Cardiff, UK – The United Kingdom’s National Health Service (NHS) has launched a groundbreaking study, dubbed GlobalMinds, to analyze the DNA of tens of thousands of individuals in an effort to unlock the genetic factors underlying both mental health disorders and dementia, potentially ushering in a new era of personalized medicine.
The ambitious, three-year project, a collaboration between researchers at Cardiff University and Akrivia Health, will fuse genetic information with existing NHS patient records and detailed questionnaire responses. Approximately 50,000 adults diagnosed with conditions such as schizophrenia, bipolar disorder, or severe depression have been invited to participate, with an additional 1,000 individuals living with dementia also included in the study.
“GlobalMinds offers an unprecedented opportunity to uncover the many personal and biological factors behind these conditions,” said Professor James Walters, the study’s lead researcher, according to reporting from boerse-global.de. “The direct comparison across different disease patterns could identify genetic risk factors that have previously remained hidden.”
A key focus of the research will be early-onset dementia, which affects individuals before the age of 65. Diagnosing this form of dementia can be particularly challenging, as symptoms like memory lapses or personality changes are often initially attributed to stress or burnout. Researchers hope a genetic fingerprint could accelerate the diagnostic process.
The study’s approach builds on growing evidence that lifestyle factors play a significant role in dementia prevention. Research from the Rush University Medical Center in the United States suggests that lifelong mental activity can reduce the risk of developing dementia by nearly 40 percent. The ACTIVE study further demonstrates that targeted cognitive training can significantly lower risk over a 20-year period. Experts emphasize the importance of controlling blood pressure, maintaining a balanced diet, engaging in regular exercise and fostering active social participation.
GlobalMinds represents a shift towards precision medicine, mirroring advancements in cancer therapy where individual genetic profiles are used to identify risk groups and tailor treatments. This approach is particularly relevant for early-onset dementia, which often has a stronger genetic component. A deeper understanding of the underlying genetics could lead to the development of new medications and revolutionize the diagnostic process.
The UK initiative is part of a broader global effort to combat dementia. Germany’s Alzheimer Forschung Initiative (AFI) is currently funding 18 new projects, ranging from the molecular origins of the disease to novel diagnostic methods. An international expansion of the GlobalMinds study is also planned, according to reports.
Trial Deck, a company specializing in clinical trial support, has developed custom APIs to facilitate large-scale data capture and automation for the GlobalMinds study, drawing data from numerous NHS Trusts and providing a secure, searchable interface for researchers. The project will combine data collected through one-to-one interviews with genetic data obtained from blood samples and anonymized NHS health records held within the Akrivia platform.
